** H-shares of BeiGene 6160.HK jump 4.9% to HK$128.2, highest since Oct. 30
** Stock set for third consecutive session of gains
** Shanghai stock 688235.SS of the Chinese oncology treatments developer rises 2.5% to 180.39 yuan
** BeiGene says few of its oncology products will be included in the National Medical Insurance Drug Catalog effective Jan. 1, 2025
** Adds inclusion will benefit marketing and sales of the products
** YTD, Hong Kong stock gains 11% vs Shanghai shares' 30.4% rise
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。